SCHEMBL6795119

SCHEMBL6795119

COc1ccc(/C=C2/N=C(c3ccccc3O)OC2=O)cc1OC

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MASP2 O00187 2/20 0.80
F2 P00734 2/20 0.63
KMT2A Q03164 4/20 0.62
MEN1 O00255 2/20 0.62
CYP1A2 P05177 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
ERO1A Q96HE7 1/20 0.57
POLB P06746 1/20 0.55
KDM4E B2RXH2 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
GAA P10253 1/20 0.53
ALDH1A1 P00352 3/20 0.52
MAPT P10636 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
HDAC3 O15379 1/20 0.51
STK17B O94768 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795121 1.00 MASP2 (0.80) MASP2F2KMT2AMEN1CYP1A2
SCHEMBL25054016 0.89 MASP2 (1.00) MASP2F2KMT2AMEN1CYP1A2
SCHEMBL6794706 0.87 MASP2 (0.82) MASP2F2KMT2AMEN1CYP1A2
SCHEMBL6794709 0.87 MASP2 (0.82) MASP2F2KMT2AMEN1CYP1A2
SCHEMBL6789975 0.83 KMT2A (0.81) MASP2F2KMT2AMEN1CYP1A2
SCHEMBL6789979 0.83 KMT2A (0.81) MASP2F2KMT2AMEN1CYP1A2
SCHEMBL15421499 0.83 KMT2A (0.81) MASP2F2KMT2AMEN1CYP1A2
SCHEMBL6795716 0.78 MASP2 (0.67) MASP2F2KMT2AMEN1CYP1A2
SCHEMBL6795718 0.78 MASP2 (0.67) MASP2F2KMT2AMEN1CYP1A2
SCHEMBL15421745 0.77 POLB (0.79) MASP2F2KMT2AMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US claimed
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis APP, PSEN1, PSEN2 MASP2 1759/4885F2 3941/4885KMT2A 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.